Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 81

1.

Treatment of community-acquired pneumonia in outpatients: randomized study of clarithromycin alone versus clarithromycin and cefuroxime.

Rovira E, Martínez-Moragón E, Belda A, Gonzalvo F, Ripollés F, Pascual JM.

Respiration. 1999;66(5):413-8.

PMID:
10516537
2.
3.

Macrolide therapy for community-acquired pneumonia due to atypical pathogens: outcome assessment at an early time point.

File TM Jr, Eckburg PB, Talbot GH, Llorens L, Friedland HD.

Int J Antimicrob Agents. 2017 Aug;50(2):247-251. doi: 10.1016/j.ijantimicag.2017.01.043. Epub 2017 Jun 6.

PMID:
28599867
4.

Azithromycin vs cefuroxime plus erythromycin for empirical treatment of community-acquired pneumonia in hospitalized patients: a prospective, randomized, multicenter trial.

Vergis EN, Indorf A, File TM Jr, Phillips J, Bates J, Tan J, Sarosi GA, Grayston JT, Summersgill J, YU VL.

Arch Intern Med. 2000 May 8;160(9):1294-300.

PMID:
10809032
5.
6.

A cost-effectiveness analysis of antimicrobial treatment of community-acquired pneumonia taking into account resistance in Belgium.

Martin M, Moore L, Quilici S, Decramer M, Simoens S.

Curr Med Res Opin. 2008 Mar;24(3):737-51. doi: 10.1185/030079908X273336. Epub 2008 Jan 28.

PMID:
18230196
7.
8.

Hospitalization rates among patients with community-acquired pneumonia treated with telithromycin vs clarithromycin: results from two randomized, double-blind, clinical trials.

Niederman MS, Chang JR, Stewart J, Asche CV, Lavin B, Nusrat R, Sullivan SD.

Curr Med Res Opin. 2004 Jul;20(7):969-80.

PMID:
15265241
9.

[Prospective and comparative study between cefuroxime, ceftriaxone and amoxicillin-clavulanic acid in the treatment of community-acquired pneumonia].

Sánchez ME, Gómez J, Gómez Vargas J, Baños V, Ruiz Gómez J, Muñoz L, Simarro E, Soto MC, Canteras M, Valdés M.

Rev Esp Quimioter. 1998 Jun;11(2):132-8. Spanish.

PMID:
9795298
10.

Comparison of hospitalization rates in patients with community-acquired pneumonia treated with 10 days of telithromycin or clarithromycin.

Niederman MS, Chang JR, Stewart J, Nusrat R, Nieman RB.

Curr Med Res Opin. 2004 May;20(5):749-56. Erratum in: Curr Med Res Opin. 2004 Aug;20(8):1331.

PMID:
15140342
11.

Cefuroxime compared to amoxicillin-clavulanic acid in the treatment of community-acquired pneumonia.

Lim TK.

Singapore Med J. 1997 Mar;38(3):139. No abstract available.

PMID:
9269388
12.

Efficacy of a three day course of azithromycin in moderately severe community-acquired pneumonia.

Rizzato G, Montemurro L, Fraioli P, Montanari G, Fanti D, Pozzoli R, Magliano E.

Eur Respir J. 1995 Mar;8(3):398-402.

13.

[Clinical efficacy of oral clarithromycin monotherapy in patients with mild or moderate community-acquired pneumonia].

Fujiki R, Rikimaru T, Aizawa H, Kawayama T.

Jpn J Antibiot. 2003 Dec;56(6):712-8. Japanese.

PMID:
15007880
15.

Comparison of hospitalization rates in patients with community-acquired pneumonia treated with telithromycin for 5 or 7 days or clarithromycin for 10 days.

Tellier G, Chang JR, Asche CV, Lavin B, Stewart J, Sullivan SD.

Curr Med Res Opin. 2004 May;20(5):739-47. Erratum in: Curr Med Res Opin. 2004 Aug;20(8):1331.

PMID:
15140341
16.

Clinical use of cefuroxime in paediatric community-acquired pneumonia.

Olivier C.

Paediatr Drugs. 2000 Sep-Oct;2(5):331-43. Review.

PMID:
11022795
17.

Sequential therapy with cefuroxime followed by cefuroxime axetil in community-acquired pneumonia.

Van den Brande P, Vondra V, Vogel F, Schlaeffer F, Staley H, Holmes C.

Chest. 1997 Aug;112(2):406-15.

PMID:
9266876
18.

Comparing gatifloxacin and clarithromycin in pneumonia symptom resolution and process of care.

Dean NC, Sperry P, Wikler M, Suchyta MS, Hadlock C.

Antimicrob Agents Chemother. 2006 Apr;50(4):1164-9.

19.

Usefulness of betalactam therapy for community-acquired pneumonia in the era of drug-resistant Streptococcus pneumoniae: a randomized study of amoxicillin-clavulanate and ceftriaxone.

Rosón B, Carratalà J, Tubau F, Dorca J, Liñares J, Pallares R, Manresa F, Gudiol F.

Microb Drug Resist. 2001 Spring;7(1):85-96.

PMID:
11310807
20.

Severe community-acquired pneumonia caused by atypical organisms.

Monsieur I, Meysman M, Vincken W, Huyghens L, Lauwers S.

Acta Clin Belg. 1997;52(2):112-5.

PMID:
9204587

Supplemental Content

Support Center